Value
5.8/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.9 |
| Analyst target | 9.0 |
KURA · Why this verdict
Why Kura Oncology (KURA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.6/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock offers a large asymmetric risk/reward setup, with analyst-target-based upside of 144% against a 15% modeled downside. Targets | The gap between the current price and the analyst-target-based take-profit level should narrow over the next 12 months. | →Stable |
| CounterThe analyst-target upside may be unreliable for a low-quality, earnings-missing biotech, and could reflect thin or stale sell-side coverage rather than achievable value. | ||
Kura Oncology has missed EPS estimates in all of the last four quarters (average surprise -56.8%), a persistent execution problem rather than a one-off. Earnings | The company needs to post at least one earnings beat in its next report to break the miss streak. | →Stable |
| CounterClinical-stage biotechs routinely miss EPS estimates by design due to R&D spend timing, so the streak may not indicate operational failure. | ||
Reported revenue growth remains strong (30% YoY per the growth notes) even though the overall quality score sits below the floor due to cash burn. Growth breakdown | Revenue growth should stay materially positive, offsetting the cash-burn concern. | →Stable |
| CounterCash-burning FCF at -181% of revenue means growth is being purchased at an unsustainable cost that could reverse once financing tightens. | ||
Insiders have been net sellers (five sales totaling $989,048, zero buys), generating a bearish internal signal that suggests limited conviction in near-term upside. Insider | The insider signal should shift toward neutral or bullish if the upside thesis is credible. | →Stable |
| CounterSmall-dollar, pre-scheduled selling plans (Rule 10b5-1) by biotech insiders are common and don't necessarily reflect a negative view on the stock. | ||
The stock is overbought (RSI 83) after a run above its 200-day moving average with rising volume, indicating momentum-driven speculative interest rather than fundamentals-driven demand. Momentum breakdown | RSI should cool from overbought levels without a sharp price breakdown if the rally is healthy. | →Stable |
| CounterPersistently overbought conditions in a low-float biotech can also precede a sharp reversal once momentum traders exit. | ||
The stock offers a large asymmetric risk/reward setup, with analyst-target-based upside of 144% against a 15% modeled downside.
→StableTargets
- Expectation
- The gap between the current price and the analyst-target-based take-profit level should narrow over the next 12 months.
CounterThe analyst-target upside may be unreliable for a low-quality, earnings-missing biotech, and could reflect thin or stale sell-side coverage rather than achievable value.
Kura Oncology has missed EPS estimates in all of the last four quarters (average surprise -56.8%), a persistent execution problem rather than a one-off.
→StableEarnings
- Expectation
- The company needs to post at least one earnings beat in its next report to break the miss streak.
CounterClinical-stage biotechs routinely miss EPS estimates by design due to R&D spend timing, so the streak may not indicate operational failure.
Reported revenue growth remains strong (30% YoY per the growth notes) even though the overall quality score sits below the floor due to cash burn.
→StableGrowth breakdown
- Expectation
- Revenue growth should stay materially positive, offsetting the cash-burn concern.
CounterCash-burning FCF at -181% of revenue means growth is being purchased at an unsustainable cost that could reverse once financing tightens.
Insiders have been net sellers (five sales totaling $989,048, zero buys), generating a bearish internal signal that suggests limited conviction in near-term upside.
→StableInsider
- Expectation
- The insider signal should shift toward neutral or bullish if the upside thesis is credible.
CounterSmall-dollar, pre-scheduled selling plans (Rule 10b5-1) by biotech insiders are common and don't necessarily reflect a negative view on the stock.
The stock is overbought (RSI 83) after a run above its 200-day moving average with rising volume, indicating momentum-driven speculative interest rather than fundamentals-driven demand.
→StableMomentum breakdown
- Expectation
- RSI should cool from overbought levels without a sharp price breakdown if the rally is healthy.
CounterPersistently overbought conditions in a low-float biotech can also precede a sharp reversal once momentum traders exit.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Kura Oncology offers a large asymmetric setup (144% modeled upside) backed by 30% revenue growth, but a four-quarter EPS miss streak, bearish insider selling, and overbought momentum argue the setup is far riskier than the headline upside suggests.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Net margin | 0.0 |
| Current ratio | 6.9 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -181% of revenue
- ▸Quality concerns
Growth
9.9/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 9.9 |
- ▸Strong growth: 30% YoY
Momentum
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.7 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.4 |
- ▸Overbought (RSI 86)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.0 |
| Analyst rating | 8.4 |
| Price target | 10.0 |
- ▸Analyst upside: 157%
Insider
5.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
- ▸Notable insider selling — $989,048 (0.101% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.9 |
| quality rank | 0.0 |
| growth rank | 6.0 |
Technical
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.4 |
| support resistance | 0.0 |
| 52w position | 9.4 |
| gap | 6.0 |
Risk (lower is worse)
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.8 |
| days to cover | 3.9 |
| volatility | 1.6 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 9.1 |
- ▸High short interest justified: 17%
- ▸Elevated put/call: 4.75
- ▸High IV: 108%
- ▸Above max pain $9
Catalyst
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 0B/4M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:7.2>=5.5
- ASYMMETRY:8.2>=1.5
- INSIDER:OK
- EARNINGS_PROXIMITY:30d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
8.25
Upside
+123.7%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 9.9 could not lift the engine output above the verdict floor.
The strongest dimensions are Growth at 9.9, Sentiment at 7.8, and Momentum at 7.2; the weakest are Quality at 2.4, Catalyst at 3.0, and Peer rank at 3.3. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 8.25 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Large Asymmetric Upside
Trip ifThe stock stays below $15 for 2 consecutive quarters, less than half the implied 144% upside to the $27.12 take-profit level.
- P2Earnings Miss Streak
Trip ifThe company misses EPS estimates for a 5th consecutive quarter, extending the average surprise below -56.8%.
- P3Growth Despite Cash Burn
Trip ifRevenue growth falls below 15% YoY, less than half the current 30% pace.
- P4Bearish Insider Signal
Trip ifNet insider selling exceeds $1,000,000 over the next 90 days, extending the current bearish signal.
- P5Overbought Momentum
Trip ifRSI stays above 80 for more than 4 consecutive weeks without a pullback below 70.